{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-292611","form_type":"8-K","ticker":null,"cik":"0001492674","company_name":"T2 Biosystems, Inc.","filed_at":"2022-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.834547+00:00","generated_at":"2026-06-21T13:03:12.994419+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"T2 Biosystems receives Nasdaq delisting notice for MVLS below $35M minimum","bullets":["Received Nasdaq deficiency letter on Nov 22, 2022 for MVLS < $35M for 30 consecutive business days.","Has 180 days, until May 22, 2023, to regain compliance under Nasdaq Listing Rule 5550(b)(2).","Can regain compliance if MVLS closes at $35M+ for 10 consecutive business days.","No immediate effect on listing or trading of common stock; delisting possible if not cured.","Company may consider extension or appeal to Nasdaq Hearings Panel if non-compliance persists."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-292611","json":"https://secwatch.observer/filing/0001193125-22-292611.json","markdown":"https://secwatch.observer/filing/0001193125-22-292611.md","text":"https://secwatch.observer/filing/0001193125-22-292611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492674/000119312522292611/0001193125-22-292611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492674/000119312522292611/d396110d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:03:12.994419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07e835f1a768a39fcee9d5bcf9047b40fbf3b88a","claim":"T2 Biosystems, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"November 22, 2022, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (“MVLS”) had been below the $35 million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until May 22, 2023, to regain compliance. The letter states that the","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1492674/000119312522292611/0001193125-22-292611-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}